Stay updated with breaking news from Hematologic Cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic
Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.
The "Hemato Oncology Testing Market by Product Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User Global
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...